RU2018137721A3 - - Google Patents

Download PDF

Info

Publication number
RU2018137721A3
RU2018137721A3 RU2018137721A RU2018137721A RU2018137721A3 RU 2018137721 A3 RU2018137721 A3 RU 2018137721A3 RU 2018137721 A RU2018137721 A RU 2018137721A RU 2018137721 A RU2018137721 A RU 2018137721A RU 2018137721 A3 RU2018137721 A3 RU 2018137721A3
Authority
RU
Russia
Application number
RU2018137721A
Other versions
RU2018137721A (ru
RU2782336C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018137721A publication Critical patent/RU2018137721A/ru
Publication of RU2018137721A3 publication Critical patent/RU2018137721A3/ru
Application granted granted Critical
Publication of RU2782336C2 publication Critical patent/RU2782336C2/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4712Muscle proteins, e.g. myosin, actin, protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2018137721A 2016-05-13 2017-05-10 Способы прогнозирования применимости белков или белковых фрагментов для иммунотерапии RU2782336C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2016/060897 2016-05-13
PCT/EP2016/060897 WO2017194170A1 (en) 2016-05-13 2016-05-13 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
PCT/EP2017/061196 WO2017194610A1 (en) 2016-05-13 2017-05-10 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

Publications (3)

Publication Number Publication Date
RU2018137721A RU2018137721A (ru) 2020-06-15
RU2018137721A3 true RU2018137721A3 (ru) 2020-08-25
RU2782336C2 RU2782336C2 (ru) 2022-10-25

Family

ID=

Also Published As

Publication number Publication date
AU2017264546A1 (en) 2018-10-18
EP3455625A1 (en) 2019-03-20
MA43794A (fr) 2019-03-20
AU2022209286A1 (en) 2022-08-25
RU2018137721A (ru) 2020-06-15
KR20190008218A (ko) 2019-01-23
LT3455625T (lt) 2021-01-11
KR102358620B1 (ko) 2022-02-07
HRP20240704T1 (hr) 2024-09-27
EP4411376A2 (en) 2024-08-07
KR20220020993A (ko) 2022-02-21
EP3792628A3 (en) 2021-05-19
SI3455625T1 (sl) 2021-01-29
EP3455625B1 (en) 2020-09-02
PT3455625T (pt) 2020-10-22
IL262680B2 (en) 2023-08-01
WO2017194610A1 (en) 2017-11-16
IL262680A (en) 2018-12-31
JP2024112805A (ja) 2024-08-21
JP2022081492A (ja) 2022-05-31
JP2019520554A (ja) 2019-07-18
PT3792628T (pt) 2024-06-18
BR112018073221A2 (pt) 2019-02-19
SI3792628T1 (sl) 2024-08-30
LT3792628T (lt) 2024-06-25
ES2826480T3 (es) 2021-05-18
HUE052240T2 (hu) 2021-04-28
CY1123520T1 (el) 2022-03-24
MX2018013081A (es) 2019-01-24
ZA201805809B (en) 2020-12-23
CA3022654A1 (en) 2017-11-16
JP7529381B2 (ja) 2024-08-06
SG11201808495SA (en) 2018-10-30
KR20240146087A (ko) 2024-10-07
MD3455625T2 (ro) 2020-12-31
FI3792628T3 (fi) 2024-06-07
EP3792628B1 (en) 2024-04-24
IL300841A (en) 2023-04-01
PL3455625T3 (pl) 2021-01-25
RS61071B1 (sr) 2020-12-31
IL262680B1 (en) 2023-04-01
CN109073637A (zh) 2018-12-21
DK3792628T3 (da) 2024-06-17
DK3455625T3 (da) 2020-10-26
WO2017194170A1 (en) 2017-11-16
MA43794B1 (fr) 2020-12-31
EP3792628A2 (en) 2021-03-17
JP2024096712A (ja) 2024-07-17
RS65568B1 (sr) 2024-06-28
ES2980781T3 (es) 2024-10-03
US20190178871A1 (en) 2019-06-13
HRP20201671T1 (hr) 2021-03-05
PL3792628T3 (pl) 2024-07-15
AU2017264546B2 (en) 2022-04-28
MX2022007902A (es) 2022-07-21

Similar Documents

Publication Publication Date Title
BR112018068177A2 (ru)
BR122020014835A2 (ru)
BR112019000402A2 (ru)
BR112019008089A2 (ru)
BR122022020382A2 (ru)
BR112019009269A2 (ru)
CN303543804S (ru)
CN303545095S (ru)
CN303538744S (ru)
CN303539498S (ru)
CN303539646S (ru)
CN303539683S (ru)
CN303541243S (ru)
CN303546742S (ru)
CN303542177S (ru)
CN303542399S (ru)
CN303542459S (ru)
CN303542470S (ru)
CN303542845S (ru)
CN303542968S (ru)
CN303543097S (ru)
CN303543347S (ru)
CN303543693S (ru)
CN303547385S (ru)
CN303538022S (ru)

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant